IGF1 and neoplasm: First, CR increases tumor cells’ sensitivity to anticancer therapy by promoting apoptosis within tumors, which reduces levels of growth factors such as insulin-like growth factor-1 (IGF-1), and by inducing autophagy via the activation of AMP-activated protein (AMPK)/the mammalian target of rapamycin (mTOR) pathway.